Mastonisin-Forte

Therapeutic indications:

MASTONISIN-FORTE is used to treat cows with clinical and subclinical mastitis of bacterial etiology during lactation, as well as with chronic and subclinical endometritis of bacterial etiology.

Composition of the veterinary drug:

10 (20) ml of the drug contains:

•          1 200 000 (2 400 000) МЕ of nisin,

•          1.5 (3.0) mg of polymyxin B.

Pharmacological activity:

Nisin, the active ingredient of the drug, is an antimicrobial peptide produced by Lactococcus lactis, which exhibits bactericidal and bacteriostatic properties against gram-positive, spore-forming and some acid-resistant microorganisms, including Streptococcus spp., Staphylococcus spp., Corynebacterium spp., Bacillus spp. etc.

Nisin reveals its bactericidal effect through the destructive action on the bacterial cytoplasmic membrane. The bacteriostatic effect of nisin is related to its interaction with the precursor of peptidoglycan, lipid Ⅱ, which leads to inhibition of bacterial cell wall synthesis. Up to date there are no cases of the microorganisms’ resistance to nisin.

Polymyxin B is a peptide antibiotic produced by Paenibacillus polymyxa, another active substance of the drug. Polymyxin B has bactericidal activity against gram-negative bacteria (Escherichia coli, Proteus spp., Klebsiella spp. and so on).

Polymyxin B binds to phospholipids in cytoplasmic membrane of bacterial cells and increases membrane permeability, which leads to the cell lysis. In therapeutic concentration polymyxin B absorbs endotoxins formed during bacterial lysis, wich contributes to the reduction of inflammatory reactions.

When administered via intramammary or intrauterine injection, MASTONISIN-FORTE is poorly absorbed into the blood and reveals antibacterial effect only in the treated udder quarter or uterine cavity.

Dosage:

MASTONISIN-FORTE is used in cows with subclinical and clinical mastitis of bacterial etiology during lactation.

Before using the drug in mastitis treatment, the content of the affected parts of the udder are milked out, the skin of the nipples is treated with an antiseptic solution, then the tip of the syringe is inserted into the nipple canal and the drug are carefully squeezed out. After the drug is injected, the syringe tip is removed, the top of the nipple is pinched with finger, and the nipple is gently massaged from bottom to top for better distribution of the drug. Before use, the drug is recommended to be heated to the body temperature of the animal.

In case of subclinical and clinical mastitis, the drug is administered intracisternally at a dose of 10 ml into each affected part of the udder once or twice a day for 2–6 days (depending on the form and severity of mastitis).

In case of endometritis, sanitary treatment of external genitalia and tail root is performed before intrauterine administration of the drug. If necessary, remove inflammatory exudate from uterine cavity of cows. Connect syringe with a catheter (pipette), put glove on the hand and rectally fix the cow's uterine cervix, then carefully insert the catheter through the cervix into the uterine cavity and squeeze out the syringe contents.

In chronic endometritis, the drug is injected into the uterine cavity at a dose of 20 ml three times at an interval of 72 hours.

In subclinical form of endometritis, the drug is administered into the uterine cavity at a dose of 20 ml, once.

Contraindications:

The use of the drug is contraindicated in animals with increased individual sensitivity to the components of the drug.

Overdose:

No overdose symptoms have been observed following administration of the drug in animals.

Pregnancy and lactation:

The drug is used during lactation. The use of the drug in pregnant animals is not contraindicated.

Special indications:

No specific effects of the drug upon first use or upon its cancellation have been identified.

Side effects and individual intolerance:

No specific effects of the drug upon first use or upon its cancellation have been identified. Missing a scheduled administration of the drug in animals should be avoided, as this may lead to reduced therapeutic efficacy. If a dose is missed, the treatment course should be resumed in accordance with the prescribed dose and dosing regimen. The missed dose should not be compensated for by increasing the dose.

Side effects and individual intolerance:

When the drug is used at the recommended doses, side effects and complications are generally not observed. In animals with increased individual sensitivity to the components of the drug, allergic reactions may occur. In such cases, the use of the drug should be discontinued, and if necessary, antihistamines and symptomatic treatment should be administered.

Interaction with other veterinary drugs:

The use of the drug does not preclude the use of other medicinal products, except for intracisternally administered drugs.

Withdrawal period:

Milk collected from the healthy udder quarters as well as after intrauterine administration of the drug may be used for human consumption without any restrictions.

Milk after intracisternal administration of the drug may be used for food purposes not earlier than 48 hours with three times daily milking or 60 hours with two times daily milking after the last administration of the drug, provided full clinical recovery.

No withdrawal period for meat. 

Storage conditions:

Store in a dark place at a temperature between 2 °C to 25 °C.

Shelf-life:

Shelf-life of the veterinary drug is 12 months from the date of manufacture. After opening the package, the drug is not suitable for storage.